The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event preventionOzyilmaz, A., Boersma, C., Visser, S. T., Postma, M. J., de Jong-van den Berg, L. T. W., Lambers-Heerspink, H. J., de Jong, P. E. & Gansevoort, R. T., May-2016, In : European Journal of Preventive Cardiology. 23, 8, p. 847-855 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacoepidemiology and Pharmacoeconomics
- PharmacoTherapy, Epidemiology and Economics
- Microbes in Health and Disease (MHD)
- Methods in Medicines evaluation & Outcomes research (M2O)
- Groningen Kidney Center (GKC)
- Cardiovascular Centre (CVC)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
Background: It is not clear which hypercholesterolemic patients benefit most from beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors with respect to the prevention of cardiovascular events. Early signs of atherosclerotic vascular damage may identify high-risk patients.
Design: We studied whether subjects with hypercholesterolemia will benefit more from starting statin treatment in the case of high albuminuria and/or high-sensitivity C-reactive protein (hsCRP).
Methods: Included were subjects who had hypercholesterolemia at baseline, a negative cardiovascular disease history and who were not treated with statins. In total, 2011 subjects were analysed, of whom 695 started with a statin during a follow-up of 7.0 +/- 1.7 years. Adjusted hazard ratios (HRs) for cardiovascular events were calculated in subjects who started versus those who did not start a statin stratified for albuminuria less than or >= 15mg/day and/or hsCRP less than or >= 3mg/L.
Results: The start of a statin was associated with a beneficial effect on cardiovascular risk in subjects with high albuminuria (HR 0.38 (0.23-0.60)), while the effect of starting a statin was non-significant in subjects with low albuminuria (HR 0.74 (0.44-1.24), P for interaction
Conclusions: The start of statin treatment is associated with a significantly lower absolute as well as relative risk of cardiovascular events in subjects with hypercholesterolemia and elevated albuminuria, whereas these drugs had less effect in subjects with normal albuminuria.
|Number of pages||9|
|Journal||European Journal of Preventive Cardiology|
|Early online date||10-Sep-2015|
|Publication status||Published - May-2016|
- Albuminuria, high-sensitivity C-reactive protein, HMG-CoA reductase inhibitor, cardiovascular event, KIDNEY-DISEASE MEASURES, STAGE RENAL-DISEASE, RISK, METAANALYSIS, INFLAMMATION, INDIVIDUALS, MORTALITY, MICROALBUMINURIA, HYPERTENSION, PRAVASTATIN